,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2018-09-11 06:12:00,"If you are still holding on to shares of OracleORCL in your portfolio, it is time you dump them as chances of favorable returns in the near term appear bleak.",0.044270481914281845,0.355657160282135,0.6000723242759705,neutral,-0.31138667464256287
1,2018-09-11 06:12:00,"Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns.",0.7687998414039612,0.013329633511602879,0.21787050366401672,positive,0.7554702162742615
2,2018-09-11 06:12:00,One such stock that you may want to drop is Oracle.,0.020154763013124466,0.14030008018016815,0.8395451903343201,neutral,-0.12014532089233398
3,2018-09-11 06:12:00,It has witnessed a significant price decline in the past one year and negative earnings estimate revisions for the fiscal 2019 and fiscal 2020.,0.017614882439374924,0.9684823751449585,0.013902755454182625,negative,-0.9508674740791321
4,2018-09-11 06:12:00,"Further, the company's Zacks Rank #4 (Sell) only highlights its innate weakness.",0.13979507982730865,0.7592124938964844,0.10099249333143234,negative,-0.6194174289703369
5,2018-09-11 06:12:00,Oracle's shares have declined 7.4% in the past year against the industry 's growth of 31.5%.,0.01835482008755207,0.9710792899131775,0.010565965436398983,negative,-0.9527244567871094
6,2018-09-11 06:12:00,"Why Oracle Should be Avoided

The share price decrease can possibly be attributed to the new accounting standard adopted by the company and the structural changes which it has undergone in the fourth quarter.",0.2109507918357849,0.249939426779747,0.5391097664833069,neutral,-0.0389886349439621
7,2018-09-11 06:12:00,"Consequently, the company now reports its new software licenses under its new Cloud license and on-premise license segment.",0.05345328524708748,0.0043960437178611755,0.9421506524085999,neutral,0.0490572415292263
8,2018-09-11 06:12:00,"Further, the company merged its Cloud SaaS, Cloud PaaS and IaaS along with its software license updates and product support into Cloud services and license support.",0.12628011405467987,0.006074328441172838,0.8676455616950989,neutral,0.12020578235387802
9,2018-09-11 06:12:00,"Oracle no longer intends to break out its cloud revenues and does not provide any guidance on SaaS, Cloud PaaS and IaaS.",0.01238758023828268,0.08932100236415863,0.8982914090156555,neutral,-0.07693342119455338
10,2018-09-11 06:12:00,This move is likely to aggravate investor concern regarding the company's outlook.,0.6515801548957825,0.044624634087085724,0.30379518866539,positive,0.6069555282592773
11,2018-09-11 06:12:00,"Moreover, stiff competition in the cloud is expected to hurt margins and will make revenue growth difficult, going forward.",0.020003894343972206,0.9626258015632629,0.017370279878377914,negative,-0.9426218867301941
12,2018-09-11 06:12:00,"Further, large acquisitions can negatively impact the company's balance sheet in the form of a high level of goodwill and intangible assets.",0.04295000433921814,0.22142447531223297,0.7356254458427429,neutral,-0.17847447097301483
13,2018-09-11 06:12:00,"Further, lawsuits and currency volatility owing to its transitions from licensing to cloud is likely to be affect Oracle.",0.03414909541606903,0.8562577962875366,0.10959309339523315,negative,-0.8221086859703064
14,2018-09-11 06:12:00,"For the full year 2019, we have witnessed four estimates moving south in the past 60 days.",0.03793785721063614,0.017369579523801804,0.9446925520896912,neutral,0.020568277686834335
15,2018-09-11 06:12:00,This trend has caused the consensus estimate to trend downward from $3.38 per share to its current level of $3.37.,0.019657349213957787,0.9631595015525818,0.01718316413462162,negative,-0.9435021281242371
16,2018-09-11 06:12:00,"Additionally, for the full year 2020, Oracle has seen three downward estimate revisions, dragging the consensus estimate down to $3.67 per share from $3.69 per share in the past 60 days.",0.018870221450924873,0.9674369692802429,0.013692807406187057,negative,-0.948566734790802
17,2018-09-11 06:12:00,"Moreover, combined with other unfavorable factors like low return on equity (ROE) and low return on Asset and low return on capital (ROC), the stock looks very unattractive.",0.022403879091143608,0.9268493056297302,0.05074680596590042,negative,-0.9044454097747803
18,2018-09-11 06:12:00,"Oracle currently trades at a ROE of 25.6%, lower than the industry average of 32.2%.",0.017810476943850517,0.9557298421859741,0.02645961567759514,negative,-0.9379193782806396
19,2018-09-11 06:12:00,"Moreover, its ROA and ROC looks very uninspiring.",0.052949536591768265,0.12654955685138702,0.8205009698867798,neutral,-0.07360002398490906
20,2018-09-11 06:12:00,"It currently trades at a ROA of 9.7% and ROC of 11.3%, compared with an average positive industry average of 11.1% and 16.6%, respectively.",0.31044167280197144,0.029655970633029938,0.6599023938179016,neutral,0.2807857096195221
21,2018-09-11 06:12:00,"Given the unfavorable factors and Zacks Rank #4, we think the shares might be at a risk.",0.1620379537343979,0.2603921890258789,0.577569842338562,neutral,-0.09835423529148102
22,2018-09-11 06:12:00,"So, it may not be a good decision to retain this stock in your portfolio anymore, at least if you don't intend to wait for a long time.",0.030760524794459343,0.0386848971247673,0.9305545687675476,neutral,-0.00792437233030796
23,2018-09-11 06:12:00,"Garmin Ltd. GRMN , Salesforce.com Inc CRM and Aspen Technology, Inc. AZPN are stocks worth considering in the broader technology sector.",0.0817900225520134,0.00742735480889678,0.9107826948165894,neutral,0.07436266541481018
24,2018-09-11 06:12:00,All the three stocks sport a Zacks Rank #1 (Strong Buy).,0.6509702205657959,0.05441093444824219,0.2946189045906067,positive,0.5965592861175537
25,2018-09-11 06:12:00,You can see the complete list of today's Zacks #1 Rank stocks here .,0.028663383796811104,0.01958855800330639,0.9517480134963989,neutral,0.009074825793504715
26,2018-09-11 06:12:00,"Long-term earnings growth rate for Garmin, Salesforce and Aspen are currently pegged at 7.35%, 25%, and 16.52%, respectively.",0.14263714849948883,0.008480296470224857,0.8488825559616089,neutral,0.13415685296058655
27,2018-09-11 06:12:00,"Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.",0.7109310626983643,0.014803656376898289,0.274265319108963,positive,0.6961274147033691
28,2018-09-11 06:12:00,New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline.,0.8527401685714722,0.013783727772533894,0.1334761381149292,positive,0.8389564156532288
29,2018-09-11 06:12:00,Early investors could realize exceptional profits.,0.8721199035644531,0.01637672632932663,0.11150334030389786,positive,0.8557431697845459
30,2018-09-11 06:12:00,"Click here to see the 5 stocks >>

Want the latest recommendations from Zacks Investment Research?",0.02363543026149273,0.017521947622299194,0.9588425755500793,neutral,0.006113482639193535
31,2018-09-11 06:12:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
32,2018-09-11 06:12:00,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
33,2018-09-11 06:12:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
